MNG657
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.417
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.417
- ESTROGEN_RESPONSE_EARLY+0.413
- COAGULATION+0.409
- HYPOXIA+0.404
- ESTROGEN_RESPONSE_LATE+0.402
- ANGIOGENESIS+0.349
- KRAS_SIGNALING_DN+0.341
- TNFA_SIGNALING_VIA_NFKB+0.337
- CHOLESTEROL_HOMEOSTASIS+0.333
Top 10 suppressed
- MYC_TARGETS_V1-0.596
- MYC_TARGETS_V2-0.581
- E2F_TARGETS-0.434
- OXIDATIVE_PHOSPHORYLATION-0.430
- G2M_CHECKPOINT-0.388
- MITOTIC_SPINDLE-0.307
- UNFOLDED_PROTEIN_RESPONSE-0.306
- WNT_BETA_CATENIN_SIGNALING-0.289
- PROTEIN_SECRETION-0.279
- DNA_REPAIR-0.256
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG931 | — | — | 0.890 |
| 2 | SRR1383059 | GTEX | — | 0.885 |
| 3 | SRR1341387 | GTEX | — | 0.880 |
| 4 | MNG113 | — | — | 0.877 |
| 5 | SRR1337412 | GTEX | — | 0.874 |
| 6 | MNG306 | — | — | 0.874 |
| 7 | SRR1341702 | GTEX | — | 0.874 |
| 8 | MNG350 | — | — | 0.872 |
| 9 | MNG349 | — | — | 0.866 |
| 10 | SRR1355150 | GTEX | — | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.417 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.417 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.413 | Inavolisib | — uncovered |
| COAGULATION | 0.409 | Binimetinib | — uncovered |
| HYPOXIA | 0.404 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.402 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.349 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.341 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.337 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.333 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.324 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.275 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.266 | Idelalisib | — uncovered |
| APOPTOSIS | 0.256 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.226 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.219 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.154 | Idelalisib | — uncovered |